IP Library Granted Patent US 10,047,150
Granted Patent B2
US 10,047,150 · App. 14/589,372 · Granted Aug 14, 2018

Anti-neublastin antibodies and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,150
App. No.
14/589,372
Granted
Aug 14, 2018
Kind
B2
Abstract

Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.

Claims (12)

1. An isolated monoclonal antibody, or antigen-binding fragment thereof, that selectively binds to the polypeptide of SEQ ID NO:1 and is produced by the hybridoma deposited in the ATCC under Accession No. PTA-7624 or PTA-7625.

2. The antigen-binding fragment of claim 1 , which is an Fab fragment, an F(ab′)2 fragment, an Fab′ fragment, an Fsc fragment, or an Fv fragment.

3. A conjugate comprising the antibody, or antigen-binding fragment thereof, of claim 1 linked to a detectable label.

4. The conjugate of claim 3 , wherein the detectable label is horseradish peroxidase or alkaline phosphatase.

5. The conjugate of claim 3 , wherein the detectable label is a fluorescent or radio-labeled marker.

6. A pharmaceutical composition comprising the antibody, or antigen-binding fragment thereof, of claim 1 and a pharmaceutically acceptable carrier.

7. An isolated cell that produces the antibody, or antigen-binding fragment thereof, of claim 1 .

8. A method of determining the presence or amount of a neublastin polypeptide in a sample, the method comprising:

contacting a sample with the antibody or antigen-binding fragment thereof of claim 1 for a time sufficient for the antibody or antigen-binding fragment thereof to bind to a neublastin polypeptide, if present in the sample; and

detecting the presence or amount of the antibody or antigen-binding fragment thereof bound to the neublastin polypeptide to thereby determine the presence or amount of the neublastin polypeptide in the sample.

9. The method of claim 8 , wherein the method comprises:

prior to the detecting step, contacting the sample with a second antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of SEQ ID NO:1 for a time sufficient for the second antibody or antigen-binding fragment thereof to bind to the neublastin polypeptide bound to the antibody or antigen-binding fragment thereof of any one of claims 1 or 3 ; and detecting the presence or amount of the second antibody or antigen-binding fragment thereof bound to the neublastin polypeptide.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2022
From: GLORIANA THERAPEUTICS, INC.
To: SINFONIA BIOTHERAPEUTICS AB
Reel/Frame 060711/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2019
From: GLORIANA THERAPEUTICS SARL
To: GLORIANA THERAPEUTICS, INC.
Reel/Frame 049005/0877 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2017
From: BIOGEN MA INC.
To: GLORIANA THERAPEUTICS SARL
Reel/Frame 041887/0117 →
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2015
From: ROSSOMANDO, ANTHONY; JIN, PING
To: BIOGEN IDEC MA INC.
Reel/Frame 034668/0043 →